← Evidence map

ArticlePharmacological research2021

Corrigendum to "Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19" [Pharmacol. Res. 164 (2021) 105402].

Emilio Di Maria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Corrigendum to "Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19" [Pharmacol. Res. 164 (2021) 105402]. | OpenQuestion